ContraFect (NASDAQ: CFRX) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares ContraFect and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraFect N/A -84.07% -44.69%
Windtree Therapeutics -1,205.47% N/A -345.52%

Analyst Ratings

This is a summary of recent recommendations and price targets for ContraFect and Windtree Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraFect 0 1 0 0 2.00
Windtree Therapeutics 0 1 0 0 2.00

Insider & Institutional Ownership

62.5% of ContraFect shares are owned by institutional investors. Comparatively, 1.5% of Windtree Therapeutics shares are owned by institutional investors. 9.3% of ContraFect shares are owned by company insiders. Comparatively, 3.5% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

ContraFect has a beta of -0.85, indicating that its share price is 185% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Earnings and Valuation

This table compares ContraFect and Windtree Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraFect N/A N/A -$28.53 million ($0.23) -4.26
Windtree Therapeutics $2.04 million 8.52 -$39.49 million ($3.59) -0.08

ContraFect has higher earnings, but lower revenue than Windtree Therapeutics. ContraFect is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

ContraFect beats Windtree Therapeutics on 6 of the 9 factors compared between the two stocks.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.